San Diego-primarily based Viking Therapeutics marked itself as a significant competitor while in the weight loss drug market place in February after revealing promising facts from a mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when offered as a weekly injection As well as in March t